Data

CanARY Study : The effect of Cannabidiol on positive psychotic symptoms in At Risk for psychosis Youth

Health Data Australia Contributor Records
Amminger, G. Paul ; Mental Health Node
Viewed: [[ro.stat.viewed]] Cited: [[ro.stat.cited]] Accessed: [[ro.stat.accessed]]
ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Adc&rfr_id=info%3Asid%2FANDS&rft_id=info:doi10.26187/XR4G-Y016&rft.title=CanARY Study : The effect of Cannabidiol on positive psychotic symptoms in At Risk for psychosis Youth&rft.identifier=http://doi.org/10.26187/XR4G-Y016&rft.publisher=Orygen&rft.description=This dataset captures data from a randomized controlled trial evaluating the feasibility of cannabidiol (CBD) as a treatment for young people aged 12-25 at Ultra-High Risk (UHR) of psychosis. It includes information on participants' adherence to the intervention, which involved daily doses of 600mg or 1000mg of CBD or a placebo over 12 weeks. The dataset records clinical assessments, adverse events, medication adherence, and biomarker data (e.g., blood, urine, hair samples) collected at multiple time points, including baseline, weeks 4, 8, 12, and follow-up visits up to 104 weeks. The primary outcome focuses on the effectiveness of CBD in reducing subthreshold psychotic symptoms.&rft.creator=Amminger, G. Paul &rft.creator=Mental Health Node &rft.date=2024&rft.relation=www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=ACTRN12621000349842&rft_subject=FOR: Mental Health&rft.type=dataset&rft.language=English Access the data
Cite Saved to MyRDA Save to MyRDA

Full description

This dataset captures data from a randomized controlled trial evaluating the feasibility of cannabidiol (CBD) as a treatment for young people aged 12-25 at Ultra-High Risk (UHR) of psychosis. It includes information on participants' adherence to the intervention, which involved daily doses of 600mg or 1000mg of CBD or a placebo over 12 weeks. The dataset records clinical assessments, adverse events, medication adherence, and biomarker data (e.g., blood, urine, hair samples) collected at multiple time points, including baseline, weeks 4, 8, 12, and follow-up visits up to 104 weeks. The primary outcome focuses on the effectiveness of CBD in reducing subthreshold psychotic symptoms.

Notes

HeSANDA 1.0.0

This dataset is part of a larger collection

Click to explore relationships graph
Help

Related Publications

  • References Cannabidiol for At Risk for psychosis Youth
    local : www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=ACTRN12621000349842

Related People

Subjects
FOR: Mental Health |

User Contributed Tags    

Login to tag this record with meaningful keywords to make it easier to discover

Identifiers